Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Republic of Georgia: These 8 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Republic of Georgia: These 8 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZYKADIA (ceritinib) generic drug versions launch in the Republic of Georgia?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Republic of Georgia Patent P20125691

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in the Republic of Georgia?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Republic of Georgia Patent P20125410

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can PRESTALIA (amlodipine besylate; perindopril arginine) generic drug versions launch in the Republic of Georgia?

Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 26, 2027
Generic Entry Controlled by: Republic of Georgia Patent P20125433
Patent Title: α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT

PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering PRESTALIA

The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. Additional details are available on the amlodipine besylate; perindopril arginine profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in the Republic of Georgia?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Republic of Georgia Patent P20125582

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the Republic of Georgia?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Republic of Georgia Patent P20125533

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can TWIRLA (ethinyl estradiol; levonorgestrel) generic drug versions launch in the Republic of Georgia?

Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Republic of Georgia Patent P20125717
Patent Title: DEVICE FOR MEDICINE DIRECT DERMAL DELIVERY

Drug Price Trends for TWIRLA
TWIRLA is a drug marketed by Agile. There are three patents protecting this drug. Two tentatively approved generics are ready to enter the market.

See drug price trends for TWIRLA.

The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in the Republic of Georgia?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Republic of Georgia Patent P20125672
Patent Title: ) SOLID COMPOSITION CONTAINING ALOGLIPTIN AND METFORMIN HYDROCHLORIDE

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Republic of Georgia?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Republic of Georgia Patent P20156282

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

Republic of Georgia Pharmaceutical Market Assessment: Branded Drugs, Generics, Regulation and Market Access

Last updated: October 14, 2026

Georgia is an import-dependent pharmaceutical market with strong retail-pharmacy concentration, high household spending, growing state purchasing, and a regulatory model designed to expand access through lower-cost generics and parallel imports. The main commercial opportunity is in affordable branded generics, chronic-disease medicines, hospital products, biosimilars, and products eligible for state reimbursement. The main risks are price compression, limited market scale, pharmacy-chain bargaining power, regulatory changes, and weak public visibility into patent and market-share data.

What is the size and structure of the Georgian pharmaceutical market?

Georgia’s pharmaceutical market is primarily supplied by imported finished products. Domestic manufacturing exists but does not materially replace imports across the full therapeutic market. Market activity is concentrated in retail pharmacy chains, distributors, private clinics, hospitals, and state-funded procurement programs.

The principal retail groups include:

  • PSP Pharmacy
  • Aversi
  • GPC Pharmacy
  • Pharmadepot
  • Smaller independent pharmacies and regional distributors

Georgia has a relatively small population of about 3.7 million. Commercial scale is therefore limited compared with Turkey, Poland, Ukraine or major European markets. Market access depends on distribution efficiency, reimbursement inclusion, retail-chain relationships and price positioning rather than volume alone.

Public market data do not consistently provide a single, audited market value covering retail, hospital and state procurement channels. The Competition and Consumer Agency has documented significant concentration in pharmaceutical distribution and retail, with large pharmacy chains holding substantial commercial influence over product availability and pricing.[1]

Market characteristic Assessment
Population base Small, approximately 3.7 million
Supply model Predominantly imported medicines
Retail structure Highly concentrated pharmacy chains
Local manufacturing Present but limited relative to imports
Reimbursement State programs, universal healthcare and disease-specific schemes
Consumer payment Historically high out-of-pocket exposure
Commercial price pressure High
Generic opportunity Strong in chronic and primary-care categories
Biosimilar opportunity Selective, mainly hospital and reimbursed channels
Patent transparency Limited compared with the United States and European Union

Georgia’s demand is concentrated in cardiovascular, gastrointestinal, endocrine, respiratory, anti-infective, pain, neurological and other chronic-care categories. Chronic medicines are particularly sensitive to affordability and reimbursement status.

How do branded and generic drugs compete in Georgia?

Generic medicines compete through lower prices, pharmacy availability, physician familiarity, distributor support and reimbursement eligibility. Branded originator products retain advantages where physicians or patients associate the brand with quality, where the product has limited generic competition, or where the treatment is used in specialist or hospital settings.

The market has several distinct product segments:

Segment Commercial characteristics
Originator brands Higher price, strongest in patented or specialist products
Branded generics Main opportunity for international manufacturers and regional suppliers
Unbranded generics Compete primarily on price and procurement tenders
Parallel imports Can materially reduce prices and challenge local distributor arrangements
Hospital medicines More dependent on tenders, clinical protocols and state purchasing
OTC products Driven by pharmacy placement, consumer recognition and promotion
Biosimilars Entry depends on procurement, substitution practice and physician confidence

Georgia’s regulatory framework permits international products to enter through recognized regulatory pathways. That lowers development costs for products already authorized in major jurisdictions. The trade-off is intense competition among imported brands and frequent pressure to reduce retail prices.

Generic companies with the strongest commercial prospects generally have:

  1. A portfolio of essential chronic medicines.
  2. EU, U.S. or other stringent-regulator approvals.
  3. Demonstrated bioequivalence and stable supply.
  4. Georgian-language packaging and compliant pharmacovigilance systems.
  5. A distributor capable of supplying the major pharmacy chains.
  6. Pricing that remains competitive after wholesale and retail margins.

What regulatory pathways are available for medicines in Georgia?

The principal legal framework is Georgia’s Law on Medicines and Pharmaceutical Activities. The regulatory authority operates under Georgia’s Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs.[2]

Georgia uses national and recognition-based registration concepts. Recognition routes can reduce the regulatory burden for products already approved by accepted foreign regulatory authorities, subject to Georgian documentation and administrative requirements. The precise route depends on the product, applicant, manufacturing site, prior authorization and dossier status.

National registration

A conventional application generally requires:

  • Administrative documentation.
  • Quality and manufacturing information.
  • Nonclinical and clinical information where applicable.
  • Product information and labeling.
  • Stability data.
  • Evidence of manufacturing compliance.
  • Bioequivalence data for relevant generic products.
  • Pharmacovigilance arrangements.
  • Samples or other materials required by the authority.

Recognition-based registration

Recognition-based procedures are commercially important for multinational and regional manufacturers. Products authorized in jurisdictions accepted by Georgian law may benefit from a shorter or less burdensome review than a full national application.

This creates an opportunity for companies with existing approvals in:

  • The European Union.
  • The United States.
  • The United Kingdom.
  • Switzerland.
  • Australia.
  • Canada.
  • Other recognized jurisdictions, depending on the applicable Georgian rule.

A foreign approval does not eliminate the need for local compliance. Applicants still need an authorized local representative, compliant labeling, supply documentation and post-market obligations.

Generic approval

Generic applicants normally must establish pharmaceutical equivalence and, where required, bioequivalence to the reference product. The applicant must also demonstrate quality, manufacturing compliance and appropriate labeling.

Georgia does not operate an Orange Book system equivalent to the U.S. Food and Drug Administration’s publication. There is no widely used public patent-listing database that automatically connects marketing authorization to enforceable patents. Patent clearance should therefore be performed separately from regulatory filing.

What is the FDA and Orange Book status of medicines in Georgia?

Georgia is not an FDA jurisdiction, and the FDA Orange Book does not determine Georgian marketing authorization. FDA approval can support recognition-based registration or regulatory credibility, but it does not itself create Georgian market authorization.

Georgia also does not have a U.S.-style public Orange Book system listing patents that block generic approval. A generic applicant should not assume that the absence of a patent listing means the product is free of patent risk. Patent exposure may arise from:

  • Compound patents.
  • Formulation patents.
  • Polymorph or salt patents.
  • Manufacturing-process patents.
  • Method-of-use patents.
  • Device or delivery-system patents.
  • Trademark and unfair-competition claims.

The practical consequence is that regulatory registration and patent freedom-to-operate are separate workstreams.

When do branded drugs lose exclusivity in Georgia?

A medicine generally loses compound-patent protection in Georgia when the relevant patent reaches its 20-year term from the filing date, subject to applicable priority, adjustment or supplementary protection rules.[3] The commercial date of generic entry can occur earlier or later depending on patent scope, regulatory approval, litigation, manufacturing readiness and distribution agreements.

Georgia is a WTO member and applies TRIPS-based intellectual-property standards. Patent rights are administered by Sakpatenti, Georgia’s National Intellectual Property Center.[4]

Exclusivity issue Georgian market implication
Compound patent May block commercial launch if valid and enforceable
Formulation patent May affect a specific dosage form or release profile
Method-of-use patent Risk depends on labeling, promotion and induced-use evidence
Process patent Can affect manufacturing route but may be harder to enforce against finished-product importation
Regulatory exclusivity Must be assessed under Georgian pharmaceutical law and applicable international obligations
Trademark rights Can continue after patent expiration and affect generic branding
Data exclusivity Requires product- and pathway-specific review; it should not be assumed to mirror U.S. rules

No comprehensive public database reliably identifies every patent relevant to each medicine sold in Georgia. A product-level patent review should examine Sakpatenti records, international patent families, local registrations, litigation records and the intended product label.

What patent litigation and Paragraph IV risks exist?

Georgia does not have a U.S.-style Paragraph IV certification system. Generic companies generally do not submit a Paragraph IV notice to an innovator as a mandatory step equivalent to the Hatch-Waxman process.

That does not remove litigation risk. Disputes may involve:

  • Patent validity.
  • Patent infringement.
  • Trademark infringement.
  • Unfair competition.
  • Parallel-import restrictions.
  • Customs enforcement.
  • Regulatory confidentiality.
  • Advertising and product claims.
  • Distribution and exclusivity contracts.

The absence of a formal Paragraph IV pathway can reduce predictable early-entry litigation, but it also provides less procedural certainty for both originators and generic applicants. A generic company may face an injunction or civil claim after launch if the patent holder identifies an enforceable right.

For originators, the lack of a public Orange Book reduces the ability to create a standardized patent-linkage barrier. For generics, the lack of a formal certification safe harbor can make launch timing more fact-specific.

What formulation and method-of-use patents matter in Georgia?

Formulation patents can remain commercially relevant after expiration of the basic compound patent. High-risk categories include:

  • Modified-release tablets.
  • Fixed-dose combinations.
  • Long-acting injectables.
  • Depot formulations.
  • Liposomal products.
  • Inhalation devices.
  • Transdermal delivery systems.
  • Pediatric formulations.
  • Stable liquid or reconstituted formulations.

A generic company may reduce exposure by launching a non-infringing dosage form, using a different excipient system or limiting its product label. That strategy requires technical and legal review because a formulation patent may cover the product’s composition, manufacturing method or performance characteristics.

Method-of-use patents are relevant where a medicine has multiple indications. A generic may attempt a skinny label that omits a patented indication. The effectiveness of that strategy depends on the approved Georgian label, promotional conduct, physician prescribing patterns and evidence of induced infringement.

How does Georgia regulate parallel imports?

Parallel importation is a central feature of the Georgian pharmaceutical model. The policy objective is to broaden supply and reduce prices by allowing products sourced from foreign markets to compete with authorized local distribution channels.

Parallel imports can create opportunities for:

  • Lower-priced originator products.
  • Cross-border sourcing from lower-price markets.
  • Expanded availability during shortages.
  • Competitive pressure on exclusive distributors.

They can also create operational risks involving:

  • Packaging and Georgian-language labeling.
  • Serialization and anti-counterfeit controls.
  • Storage and transport conditions.
  • Pharmacovigilance responsibility.
  • Product recall coordination.
  • Trademark exhaustion.
  • Differences in approved indications or presentations.
  • Distributor conflict.

The Competition and Consumer Agency has examined competition conditions in the pharmaceutical sector, including market concentration and the influence of major distributors and pharmacy networks.[1]

What is the reimbursement and procurement environment?

State purchasing and reimbursement are among the most important routes to scale. Georgia’s Universal Health Care program and disease-specific programs influence demand, particularly for medicines used in chronic conditions and hospital care.[5]

Commercial access normally requires one or more of the following:

  • Inclusion in a state reimbursement program.
  • Participation in a public procurement tender.
  • Supply through hospitals or clinics.
  • Listing with major pharmacy chains.
  • Direct physician prescribing and patient payment.
  • Distribution through regional wholesalers.

Reimbursement inclusion can increase volume but also imposes price and supply obligations. Products excluded from reimbursement may still sell through the private retail market, but demand is more exposed to household affordability.

Tender participation creates additional risks:

  • Lowest-price or price-weighted awards.
  • Short award periods.
  • Forecasting uncertainty.
  • Payment-cycle exposure.
  • Mandatory supply continuity.
  • Rapid substitution among equivalent products.

Companies should model the Georgian market through separate channels rather than using a single average price:

Channel Main decision factor
Reimbursed outpatient medicines Price, inclusion, supply continuity
Public hospitals Tender price and technical compliance
Private hospitals Clinical preference and contracting
Retail pharmacy Margin, availability, brand recognition
OTC products Consumer demand and pharmacy promotion
Specialist medicines Physician access and clinical evidence

What are the main regulatory opportunities?

The strongest opportunities are concentrated in products with established foreign approvals and clear affordability advantages.

Recognition-based entry

Companies with EU, U.S. or other accepted approvals can reduce local development and review costs. This is especially useful for mature products, branded generics and established hospital medicines.

Chronic-disease generics

Georgia’s affordability constraints support demand for cardiovascular, diabetes, respiratory and gastrointestinal generics. Products with once-daily dosing, reliable supply and clear substitution value are commercially attractive.

Biosimilars

Biosimilar opportunities exist in oncology, immunology, endocrinology and supportive care. Market entry requires more than registration. Key requirements include:

  • A credible comparability package.
  • Physician education.
  • Tender competitiveness.
  • Pharmacovigilance.
  • Hospital access.
  • Confidence in interchangeability and substitution practices.

Georgia is not an automatic biosimilar market. Uptake depends on procurement rules, specialist acceptance and the structure of reimbursement.

Local packaging and manufacturing

Local secondary packaging, quality-control operations and contract manufacturing can improve supply resilience and government relations. Full-scale manufacturing is more difficult because of limited domestic volume, capital requirements and export dependence.

Digital regulatory operations

Electronic submissions, e-prescribing, serialization and pharmacovigilance systems create opportunities for companies with stronger compliance infrastructure. Digital supply-chain controls are also relevant to counterfeit prevention and recall execution.

What are the main regulatory and commercial challenges?

Georgia’s principal challenges are structural rather than purely technical.

Small market size

Fixed regulatory, legal, pharmacovigilance and distribution costs can be high relative to attainable sales. Companies need portfolios rather than single-product strategies unless the product is high value or state funded.

Retail concentration

Major pharmacy chains can influence listing, shelf access, consumer substitution and promotional visibility. A company dependent on one distributor or one chain carries material concentration risk.

Price compression

Parallel imports, generic substitution, tenders and household affordability create continuing price pressure. Premium pricing is difficult without clinical differentiation, reimbursement support or a protected indication.

Regulatory change

Pricing, reimbursement, prescription and pharmacy rules can change through legislation or ministerial action. Companies should monitor Georgian legal amendments and administrative practice rather than rely only on the original registration pathway.

Supply continuity

Small-market launches can fail because of stockouts, weak demand forecasting, customs delays or insufficient local inventory. A registration without dependable supply has limited commercial value.

Patent uncertainty

The absence of a comprehensive public Orange Book and a formal Paragraph IV system makes launch planning less standardized. Originators and generics need independent patent, trademark and regulatory assessments.

How does Georgia compare with European Union pharmaceutical markets?

Georgia is more flexible and commercially less predictable than a mature EU market.

Issue Georgia European Union
Market size Small Large combined market
Regulatory route National and recognition mechanisms Centralized, decentralized and national procedures
Patent linkage Limited public linkage Varies by member state
Orange Book No U.S.-style equivalent No single EU Orange Book
Parallel trade Important Established but legally complex
Reimbursement More centralized and price-sensitive National HTA and reimbursement systems
Retail concentration High Varies by country
Generic entry Often price-driven More formal substitution and reimbursement rules
Biosimilar uptake Selective More mature in several states
Local manufacturing Limited Significant regional manufacturing base

Georgia can be attractive as a regional entry market, but it should not be treated as a miniature EU jurisdiction. EU approval may facilitate Georgian registration, yet EU market authorization does not guarantee Georgian reimbursement, pricing or distribution success.

What generic launch scenarios exist in Georgia?

Scenario 1: Early launch after foreign approval

A generic with a recognized foreign authorization enters through a recognition pathway, completes local requirements and launches before the originator builds a strong local legal response. This is the most efficient path where patent exposure is low.

Scenario 2: Patent-sensitive launch

The generic is registered but launch timing is controlled by compound, formulation or use patents. The company may wait for expiry, redesign the formulation or narrow the indication.

Scenario 3: Tender-led launch

The company targets state procurement or hospital tenders. Volume can increase rapidly, but price and supply obligations reduce margin.

Scenario 4: Retail branded-generic launch

The company launches through a major pharmacy chain with a Georgian brand, local promotion and distributor support. This requires consumer and physician investment and exposes the product to retail-chain bargaining power.

Scenario 5: Parallel-import competition

A lower-priced imported version reaches the market and pressures both the originator and authorized generic. Packaging, quality and supply controls become critical.

How strong is the Georgian pharmaceutical patent and regulatory environment?

Georgia’s patent environment provides basic TRIPS-aligned protection but lacks the procedural infrastructure found in the United States. Patent strength depends on the specific asset, local filing status, claim scope, enforceability and court practice.

Risk factor Originator impact Generic impact
No public Orange Book Less predictable patent linkage Less visibility into launch barriers
Parallel imports Weakens territorial price segmentation Creates sourcing opportunity
Small market Limits litigation economics Reduces expected damages but not injunction risk
Recognition pathway Accelerates competition Lowers entry cost
Retail concentration Strengthens distributor bargaining power Raises listing dependence
Reimbursement pricing Limits premium recovery Supports high-volume generics
Limited public data Reduces forecasting precision Requires primary market diligence

The strongest defensive position usually combines valid patents, a differentiated formulation, a protected or reimbursed indication, trademark control, dependable supply and strong clinical relationships. A compound patent alone may not preserve commercial share after expiry if several low-cost generics enter simultaneously.

What licensing and partnership strategies work best?

Publicly visible Georgian licensing data are limited. In practice, market entry is commonly structured through:

  • Exclusive local distribution.
  • Nonexclusive wholesaling.
  • In-licensing of branded generics.
  • Co-promotion with a local company.
  • Contract registration and pharmacovigilance services.
  • Tender partnerships.
  • Local packaging or manufacturing agreements.

An exclusive distribution agreement should address:

  • Minimum purchase commitments.
  • Reimbursement and tender participation.
  • Parallel-import handling.
  • Pharmacovigilance duties.
  • Product recalls.
  • Anti-bribery controls.
  • Forecasting and inventory.
  • Termination rights.
  • Trademark use.
  • Post-termination stock.

A company entering Georgia should avoid granting broad exclusivity without performance thresholds. The pharmacy and distributor concentration structure gives local partners leverage, but a poorly drafted agreement can prevent alternative channels.

Key Takeaways

  • Georgia is an import-dependent, price-sensitive pharmaceutical market with strong demand for affordable generics.
  • Retail pharmacy chains and distributors hold substantial commercial influence.
  • Recognition-based registration can reduce entry time for products approved by accepted foreign authorities.
  • Georgia has no U.S.-style Orange Book or mandatory Paragraph IV system.
  • Patent clearance remains necessary for compounds, formulations, manufacturing processes and methods of use.
  • Parallel imports are commercially important and can reduce originator pricing power.
  • Reimbursement and public procurement are critical for chronic medicines, hospital products and biosimilars.
  • The best opportunities are branded generics, chronic-care medicines, selected biosimilars and products with state-purchasing potential.
  • The main risks are market concentration, price compression, regulatory change, limited market scale and uncertain patent visibility.
  • Successful entrants need local regulatory representation, strong pharmacovigilance, reliable distribution and channel-specific pricing.

FAQs

Is Georgia a good market for generic drug companies?

Yes, particularly for affordable chronic-disease medicines, branded generics and products entering through recognized foreign approvals. Market size is limited, so portfolio breadth and distribution efficiency are important.

Does Georgia have an Orange Book for pharmaceutical patents?

No U.S.-style Orange Book is widely used for Georgian medicines. Patent clearance must be conducted separately through local and international patent records.

Can a generic launch in Georgia before patent expiration?

Potentially, but launch timing depends on the scope and enforceability of Georgian patents, regulatory requirements, litigation risk and the product’s formulation and indications. There is no U.S.-style Paragraph IV procedure that controls the process.

Are biosimilars commercially viable in Georgia?

They can be viable in reimbursed and hospital categories, especially where tenders reward lower prices. Uptake depends on physician confidence, procurement terms, pharmacovigilance and substitution practice.

Which companies control Georgian pharmaceutical distribution?

Aversi, PSP Pharmacy, GPC and Pharmadepot are among the most visible retail groups. Their commercial influence does not eliminate the role of independent pharmacies, hospitals, wholesalers or state procurement.

References

  1. Georgia Competition and Consumer Agency. (2022). Pharmaceutical market monitoring and competition assessment. Tbilisi, Georgia.

  2. Parliament of Georgia. (1997, as amended). Law of Georgia on Medicines and Pharmaceutical Activities. Tbilisi, Georgia.

  3. World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights. Geneva, Switzerland.

  4. National Intellectual Property Center of Georgia. (n.d.). Sakpatenti: Patent and intellectual property protection in Georgia. Tbilisi, Georgia.

  5. Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia. (n.d.). Universal health care and state health programs. Tbilisi, Georgia.

  6. World Health Organization. (2019). Georgia pharmaceutical pricing and reimbursement policy review. WHO Regional Office for Europe, Copenhagen, Denmark.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.